cefixime has been researched along with cephalexin in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (37.50) | 18.7374 |
| 1990's | 10 (25.00) | 18.2507 |
| 2000's | 9 (22.50) | 29.6817 |
| 2010's | 5 (12.50) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Inui, K; Saito, H; Yamamoto, M | 1 |
| Iseki, K; Kondo, Y; Miyazaki, K; Shiroto, H; Sugawara, M; Uchino, J | 1 |
| Allen, SD; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Pfaller, MA; Washington, JA | 1 |
| Kim, H; Kim, WJ; Ko, KY; Oh, J | 1 |
| Kalbfleisch, JH; Roberson, D; Sarubbi, F; Verghese, A | 1 |
| Nies, BA | 1 |
| Dorow, P | 1 |
| Barry, AL; Jones, RN | 1 |
| Lin, SR; Peng, CF | 1 |
| Chin, NX; Neu, HC | 1 |
| Baba, S; Itoh, Y; Kawamura, S; Kinoshita, H; Kobayashi, K; Mori, Y; Onishi, S; Shimada, J; Suzuki, K; Ueda, R | 1 |
| Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN; Thornsberry, C | 1 |
| Ayers, LW; Barry, AL; Fuchs, PC; Gavan, TL; Gerlach, EH; Jones, RN | 1 |
| Edelstein, MA; Finegold, SM; Gee, R; Ingram-Drake, L; MacDonald, K; Reinhardt, J; Wexler, H | 1 |
| Faulkner, RD; Hiltke, MF; McAteer, JA; Silber, BM | 1 |
| Blatter, MM; Bluestone, CD; Fall, P; Kenna, MA; Kurs-Lasky, M; Reisinger, KS; Stephenson, J; Wucher, FP | 1 |
| Fujishita, Y; Kaizu, M; Kojo, H; Matsumoto, Y; Shigi, Y | 1 |
| Goto, S; Kamimura, T; Kojo, H; Kuwahara, S; Matsumoto, Y; Mine, Y | 1 |
| Girbig, F; Gutjahr, U; Kowalewski, S; Kramer, W | 1 |
| Ogle, JW | 1 |
| El-Khayam, A; Godfrey, L; Katz, B; Kessler, OJ; Korzets, Z; Pomeranz, A; Wolach, B | 1 |
| Cadeddu, L; Cadoni, BM; Puxeddu, P | 1 |
| Barbagallo, S; Catena, E; Crimi, N; Dericoloso, L; Micillo, E; Mistretta, A; Tranchese, D | 1 |
| Alkharfy, KM; Najjar, TA; Saad, SY | 1 |
| Bai, AM; Cheng, LY; Hu, YJ; Li, HZ; Li, M; Ouyang, Y; Yang, CZ | 1 |
| A Ahmed, H; A Mohamed, M; Adel Pashameah, R; F Nassar, H; Y A Alanazi, T; Y Binsaleh, A | 1 |
| Clauss, W; Daniel, H; Gebert, I; Weber, WM; Weintraut, H; Wenzel, U | 1 |
| Inui, K; Mukai, M; Saito, H; Terada, T | 1 |
| Hayashi, K; Higashida, H; Miyamoto, K; Nakanishi, T; Sai, Y; Shiraga, T; Takeda, E; Tamai, I; Terao, T; Tsuji, A | 1 |
| Carter, AL; Ganapathy, ME; Ganapathy, V; Huang, W; Iseki, K; Leibach, FH; Rajan, DP; Sugawara, M | 1 |
| Brandsch, M; Luckner, P | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Aldini, G; De Luca, L; Marconi, C; Pedretti, A; Regazzoni, L; Vistoli, G | 1 |
| Grime, K; Paine, SW | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cefixime and cephalexin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for cefixime and cephalexin
| Article | Year |
|---|---|
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Cephalosporins; Clavulanic Acids; Drug Therapy, Combination; Enterococcus; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Staphylococcus; Streptococcus agalactiae | 1991 |
Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Bronchitis; Cefixime; Cefotaxime; Cephalexin; Chronic Disease; Gram-Negative Bacteria; Haemophilus Infections; Haemophilus influenzae; Humans; Moraxella catarrhalis; Pneumococcal Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 1990 |
Safety and efficacy of cefixime versus cefaclor in respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Female; Humans; Male; Middle Aged; Respiratory Tract Infections | 1989 |
[A parallel comparative double blind study of cefixime with cefaclor in the treatment of acute suppurative otitis media in children].
Topics: Acute Disease; Age Factors; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Infant; Otitis Media; Otitis Media, Suppurative | 1987 |
Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children.
Topics: Acute Disease; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Child; Child, Preschool; Female; Humans; Infant; Male; Otitis Media with Effusion; Patient Compliance | 1987 |
34 other study(ies) available for cefixime and cephalexin
| Article | Year |
|---|---|
Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes.
Topics: Amino Acids; Anti-Infective Agents, Urinary; Biological Transport; Cefixime; Cefotaxime; Cefotiam; Cell Line; Cell Membrane; Cells, Cultured; Cephalexin; Cephradine; Epithelium; Intestinal Mucosa; Intestines | 1992 |
Transport characteristics of ceftibuten, cefixime and cephalexin across human jejunal brush-border membrane.
Topics: Biological Transport, Active; Cefixime; Cefotaxime; Ceftibuten; Cephalexin; Cephalosporins; Glucose; Humans; Hydrogen; In Vitro Techniques; Jejunum; Microvilli | 1991 |
Synthesis and biological activity of novel 3-(2-propenyl)-cephalosporins. I.
Topics: Absorption; Administration, Oral; Alkenes; Animals; Bacteria; Cefixime; Cefotaxime; Cephalexin; Cephalosporins; Chromatography; Drug Evaluation, Preclinical; Kinetics; Mice; Microbial Sensitivity Tests; Molecular Structure; Rats | 1991 |
Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
Topics: Cefaclor; Cefixime; Cefotaxime; Cephalexin; Drug Resistance, Microbial; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Proteus mirabilis; Streptococcus pyogenes | 1989 |
In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Topics: Administration, Oral; Cefaclor; Cefixime; Cefotaxime; Ceftibuten; Cefuroxime; Cephalexin; Cephalosporins; Enterobacteriaceae; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseria meningitidis; Streptococcus | 1988 |
In vitro antibacterial activity of cefixime.
Topics: Amoxicillin; Ampicillin; Bacteria; Bacterial Infections; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Humans; Microbial Sensitivity Tests | 1988 |
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Cefaclor; Cefixime; Cefotaxime; Cefpodoxime; Ceftizoxime; Cefuroxime; Cephalexin; Cephalosporins; Clavulanic Acids; Culture Media; Drug Combinations; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
Topics: Amoxicillin; beta-Lactamases; Cefaclor; Cefixime; Cefotaxime; Cefuroxime; Cephalexin; Clavulanic Acid; Clavulanic Acids; Enterobacteriaceae; Escherichia coli; In Vitro Techniques; Pseudomonas; Staphylococcus | 1986 |
Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.
Topics: Bacteria; Cefixime; Cefmenoxime; Cefotaxime; Cephalexin; Cephaloridine; Cephalosporins; Enterobacteriaceae; Microbial Sensitivity Tests | 1987 |
Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.
Topics: Bacteria; Cefaclor; Cefixime; Cefotaxime; Cephalexin; Clostridium; Digestive System; Enterobacteriaceae; Feces; Humans; Intestines; Male | 1987 |
Liquid-chromatographic determination of five orally active cephalosporins--cefixime, cefaclor, cefadroxil, cephalexin, and cephradine--in human serum.
Topics: Cefaclor; Cefadroxil; Cefixime; Cefotaxime; Cephalexin; Cephalosporins; Cephradine; Chromatography, High Pressure Liquid; Humans; Reference Standards; Reference Values | 1987 |
Mechanism of action of the new orally active cephalosporin FK027.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carrier Proteins; Cefaclor; Cefixime; Cephalexin; Cephalosporins; Enterobacter; Escherichia coli; Hexosyltransferases; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Staphylococcus aureus | 1984 |
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
Topics: Amoxicillin; Animals; Bacteria; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Cefaclor; Cefixime; Cephalexin; Cephalosporins; Mice; Penicillin Resistance | 1984 |
Interaction of the orally active dianionic cephalosporin cefixime with the uptake system for oligopeptides and alpha-amino-beta-lactam antibiotics in rabbit small intestine.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biological Transport; Cefixime; Cefotaxime; Cephalexin; Drug Interactions; Hot Temperature; Hydrogen-Ion Concentration; Intestine, Small; Oligopeptides; Rabbits | 1993 |
Antimicrobial therapy for ambulatory pediatrics.
Topics: Ambulatory Care; Anti-Bacterial Agents; Anti-Infective Agents; Cefixime; Cefuroxime; Cephalexin; Cephalosporins; Child; Fluoroquinolones; Humans; Macrolides; Otitis Media; Penicillins; Pharyngitis; Pneumonia, Bacterial; Sinusitis; Urinary Tract Infections | 1999 |
A bioassay evaluation of the urinary antibacterial efficacy of low dose prophylactic antibiotics in children with vesicoureteral reflux.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biological Assay; Cefixime; Cephalexin; Child; Child, Preschool; Evaluation Studies as Topic; Female; Humans; Infant; Male; Nalidixic Acid; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections; Vesico-Ureteral Reflux | 2000 |
Cefixime: comparative clinical trial on the treatment of upper respiratory tract infection and otitis in adults.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cephalexin; Controlled Clinical Trials as Topic; Female; Humans; Male; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 1989 |
Cefixime: comparative clinical trial on the treatment of lower respiratory tract infection in adults.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bronchitis; Bronchopneumonia; Cefixime; Cephalexin; Clinical Trials as Topic; Female; Humans; Male; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections | 1989 |
Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa.
Topics: Adult; Area Under Curve; Cefixime; Cephalexin; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Mucous Membrane; Oropharynx; Saliva; Streptococcus | 2009 |
Probing the interaction of cephalosporin with bovine serum albumin: A structural and comparative perspective.
Topics: Animals; Cattle; Cefixime; Cephalexin; Circular Dichroism; Models, Molecular; Molecular Conformation; Molecular Structure; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2018 |
Condition optimization of eco-friendly RP-HPLC and MCR methods via Box-Behnken design and six sigma approach for detecting antibiotic residues.
Topics: Anti-Bacterial Agents; Cefixime; Cephalexin; Chromatography, High Pressure Liquid; Humans; Total Quality Management; Vitelliform Macular Dystrophy | 2023 |
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
Topics: Animals; Biological Transport; Caco-2 Cells; Carrier Proteins; Cephalosporins; Humans; Hydrogen-Ion Concentration; Membrane Potentials; Oocytes; Peptide Transporter 1; Rabbits; Symporters; Xenopus laevis | 1996 |
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
Topics: Animals; Anti-Bacterial Agents; Biological Transport; Carrier Proteins; Ceftibuten; Cephalosporins; Cyclacillin; Dipeptides; Hydrogen-Ion Concentration; Kidney; Kinetics; LLC-PK1 Cells; Peptide Transporter 1; Rats; Recombinant Proteins; Structure-Activity Relationship; Symporters; Transfection | 1997 |
The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Carbon Radioisotopes; Carrier Proteins; Dipeptides; Female; Intestinal Absorption; Intestine, Small; Male; Peptide Transporter 1; Rats; Rats, Sprague-Dawley; Symporters; Xenopus laevis | 1997 |
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
Topics: Acetylcarnitine; Animals; Anti-Bacterial Agents; Carnitine; Carrier Proteins; Cefadroxil; Cefepime; Cephaloridine; Cephalosporins; Dose-Response Relationship, Drug; HeLa Cells; Humans; Kinetics; Membrane Proteins; Nitrogen; Organic Cation Transport Proteins; Rats; Sodium; Solute Carrier Family 22 Member 5; Tumor Cells, Cultured | 2000 |
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
Topics: Binding Sites; Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Peptides; Protein Binding; Structural Homology, Protein; Symporters | 2011 |
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Body Weight; Dogs; Drug Administration Routes; Humans; Liver; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Pharmaceutical Preparations; Protein Binding; Rats; Species Specificity | 2013 |